carmustine has been researched along with Thrombophlebitis in 2 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Thrombophlebitis: Inflammation of a vein associated with a blood clot (THROMBUS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of dacarbazine (DTIC, 220 mg/m2) and cisplatin (DDP, 25 mg/m2) IV daily for 3 days every 3 weeks, carmustine (BCNU, 150 mg/m2) IV every 6 weeks, and tamoxifen (TAM, 10 mg orally twice daily) produced a 50% objective response rate in patients with metastatic melanoma." | 7.67 | The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. ( Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF; Sprandio, JD, 1989) |
| "Metastatic melanoma is difficult to treat because of low response rates to most chemotherapy regimens and short remission durations." | 5.29 | The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen. ( Crowell, EB; Higa, GM, 1993) |
| "The combination of dacarbazine (DTIC, 220 mg/m2) and cisplatin (DDP, 25 mg/m2) IV daily for 3 days every 3 weeks, carmustine (BCNU, 150 mg/m2) IV every 6 weeks, and tamoxifen (TAM, 10 mg orally twice daily) produced a 50% objective response rate in patients with metastatic melanoma." | 3.67 | The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. ( Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF; Sprandio, JD, 1989) |
| "Metastatic melanoma is difficult to treat because of low response rates to most chemotherapy regimens and short remission durations." | 1.29 | The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen. ( Crowell, EB; Higa, GM, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crowell, EB | 1 |
| Higa, GM | 1 |
| McClay, EF | 1 |
| Mastrangelo, MJ | 1 |
| Sprandio, JD | 1 |
| Bellet, RE | 1 |
| Berd, D | 1 |
2 other studies available for carmustine and Thrombophlebitis
| Article | Year |
|---|---|
The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Dru | 1993 |
The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Hematolo | 1989 |